Palisade Bio (PALI) Total Current Liabilities (2010 - 2026)
Palisade Bio (PALI) reported Total Current Liabilities of $5.6 million for Q1 2026, up 102.38% year-over-year from $2.8 million in Q1 2025, and up 21.23% on a QoQ basis from $4.6 million in Q4 2025.
Palisade Bio (PALI) has 17 years of Total Current Liabilities data on file, last reported at $5.6 million in Q1 2026.
- Quarterly Total Current Liabilities rose 102.38% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (up 102.38% YoY) and the FY2025 annual result came in at $4.6 million, up 43.26% from the prior year.
- Total Current Liabilities advanced to $5.6 million in Q1 2026 per PALI's latest filing, from $4.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $5.6 million in Q1 2026 and bottomed at $1.3 million in Q1 2023.
- The 5-year median for Total Current Liabilities is $2.8 million (2024), against an average of $3.0 million.
- The widest annual swing landed in 2023, when Total Current Liabilities slipped 29.45%; it then jumped 102.38% in 2026.
- Tracing PALI's Total Current Liabilities over 5 years: stood at $3.0 million in 2022, then retreated by 14.14% to $2.6 million in 2023, then advanced by 25.14% to $3.2 million in 2024, then surged by 43.26% to $4.6 million in 2025, then gained by 21.23% to $5.6 million in 2026.
- Per Business Quant, the three latest PALI Total Current Liabilities figures stand at $5.6 million (Q1 2026), $4.6 million (Q4 2025), and $3.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 5.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.62 Mn |
| Dec 31, 2025 | 4.64 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 3.97 Mn |
| Mar 31, 2025 | 2.78 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 2.68 Mn |
| Jun 30, 2024 | 2.84 Mn |
| Mar 31, 2024 | 2.47 Mn |
| Dec 31, 2023 | 2.59 Mn |
| Sep 30, 2023 | 2.65 Mn |
| Jun 30, 2023 | 2.34 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 3.01 Mn |
| Sep 30, 2022 | 3.51 Mn |
| Jun 30, 2022 | 2.86 Mn |
| Mar 31, 2022 | 1.86 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | 2.92 Mn |
| Jun 30, 2021 | 3.85 Mn |
| Mar 31, 2021 | 1.01 Mn |
| Dec 31, 2020 | 8.08 Mn |
| Sep 30, 2020 | 1.00 Mn |
| Jun 30, 2020 | 675,976.00 |
| Mar 31, 2020 | 1.19 Mn |
| Dec 31, 2019 | 1.22 Mn |
| Sep 30, 2019 | 1.58 Mn |
| Jun 30, 2019 | 1.07 Mn |
| Mar 31, 2019 | 1.21 Mn |
| Dec 31, 2018 | 1.05 Mn |
| Sep 30, 2018 | 1.18 Mn |
| Jun 30, 2018 | 766,001.00 |
| Mar 31, 2018 | 1.28 Mn |
| Dec 31, 2017 | 1.51 Mn |
| Sep 30, 2017 | 1.83 Mn |
| Jun 30, 2017 | 2.30 Mn |
| Mar 31, 2017 | 5.05 Mn |
| Dec 31, 2016 | 7.33 Mn |
| Sep 30, 2016 | 7.85 Mn |
| Jun 30, 2016 | 8.61 Mn |
| Mar 31, 2016 | 7.62 Mn |
| Dec 31, 2015 | 6.43 Mn |
| Sep 30, 2015 | 7.47 Mn |
| Jun 30, 2015 | 5.91 Mn |
| Mar 31, 2015 | 4.34 Mn |
| Dec 31, 2014 | 4.01 Mn |
| Sep 30, 2014 | 5.70 Mn |
| Jun 30, 2014 | 4.99 Mn |
| Mar 31, 2014 | 4.67 Mn |
| Dec 31, 2013 | 5.94 Mn |
| Sep 30, 2013 | 5.15 Mn |
| Jun 30, 2013 | 3.01 Mn |
| Mar 31, 2013 | 2.65 Mn |
| Dec 31, 2012 | 1.76 Mn |
| Sep 30, 2012 | 2.12 Mn |
| Jun 30, 2012 | 1.47 Mn |
| Mar 31, 2012 | 2.31 Mn |
| Dec 31, 2011 | 2.43 Mn |
| Sep 30, 2011 | 1.99 Mn |
| Jun 30, 2011 | 1.15 Mn |
| Dec 31, 2010 | 2.74 Mn |